----item----
version: 1
id: {4294EDF7-D524-4AE5-9EBA-F68B69032CCE}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/07/31/Immunomedics US beats carcinoembryonic CEA patent opposition in Europe
parent: {66DED1B6-66CF-446C-8FC9-AC5734A4B3CF}
name: Immunomedics US beats carcinoembryonic CEA patent opposition in Europe
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: ecedf657-53f8-431c-a30a-afae5c599fe2

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 265

<p><strong>[C#198600168:Immunomedics]</strong> (US) has overcome opposition from Behringwerke (Germany) to its European patent (No 131,627) covering specific antibodies for carcinoembryonic antigen (CEA), which Immunomedics uses in its CEA-Scan imaging product.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 74

Immunomedics (US) beats carcinoembryonic (CEA) patent opposition in Europe
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1112

<p><strong>[C#198600168:Immunomedics]</strong> (US) has overcome opposition from Behringwerke (Germany) to its European patent (No 131,627) covering specific antibodies for carcinoembryonic antigen (CEA), which Immunomedics uses in its CEA-Scan imaging product.</p><p>The Opposition Division of the European Patent Office issued a decision maintaining the patent. Behringwerke had requested that the patent be revoked, but is not appealing against the decision.</p><p>Immunomedics' CEA-Scan is currently under regulatory review in the US, Canada, and Europe for use in the early detection of colorectal cancer and in clinical trials for the detection of lung and breast cancers. The company submitted additional data on the product to the FDA in May, after the agency found the product not approvable last year (see Clinica No 656, p 18).</p><p>The patent also includes claims for a blood test for the detection of CEA. Immunomedics believes that other companies are currently selling such a test, and it intends "to offer licences to these companies rather than limit the public's access to these products".</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{F5161CC2-772F-472E-A21C-BF196343462E}|{2360F67B-A7D7-4E2A-9C6C-5618FAE5CB5D}|{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 70

Immunomedics US beats carcinoembryonic CEA patent opposition in Europe
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950731T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950731T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950731T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT053644
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 74

Immunomedics (US) beats carcinoembryonic (CEA) patent opposition in Europe
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198600168
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

255453
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184550Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

ecedf657-53f8-431c-a30a-afae5c599fe2
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184550Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
